All In Biotech

Drug Trial Radar · NCT01292460

Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies

A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those Given Individually in Patients With Open Angle Glaucoma or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Mar 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Planned (sponsor's estimate)

Start

Feb 2011

Primary completion

Sep 2012

Study completion Sep 2012

Sponsor

Lead sponsor
Santen OyIndustry
Sponsor type
Industry
First posted
Feb 9, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of the preservative-free fixed tafluprost-timolol combination to those of tafluprost and timolol alone. This study will enroll patients who have ocular hypertension or glaucoma and who are using timolol or prostaglandin. The study medication period is 6 months, but the primary evaluation of efficacy is done at 3 months.

Conditions

  • Ocular Hypertension
  • Open-angle Glaucoma

Interventions

  • Timolol/ FDC/ Placebo/ TafluprostDrug

    Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00). Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the average diurnal Intraocular Pressure (IOP) at 3 monthsTime frame: At 3 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Eye clinic, University Hospital of Kuopio

    Kuopio, Finland

  • Eye Clinic, University Hospital of Oulu

    Oulu, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.